Lapelga vs Gastrofil

Launched by LONDON HEALTH SCIENCES CENTRE RESEARCH INSTITUTE OR LAWSON RESEARCH INSTITUTE OF ST. JOSEPH'S · Oct 30, 2023

Keywords

ClinConnect Summary

This clinical trial is comparing two treatments for patients with multiple myeloma or lymphoma who are undergoing a specific type of stem cell transplant called autologous hematopoietic stem cell transplantation. The study is looking at LaPelga, which is a single injection of a medication called pegfilgrastim, and Gastrofil, which requires multiple injections of a similar medication called filgrastim. The goal is to see if LaPelga is just as effective as Gastrofil in helping patients recover their white blood cells, with fewer side effects and more convenience, potentially saving on costs as well.

To participate in this trial, patients need to be between 18 and 75 years old, have a diagnosis of multiple myeloma or lymphoma, and be eligible for the stem cell transplant. They must also be willing to provide written consent to join the study. Throughout the trial, participants will receive either LaPelga or Gastrofil after their stem cell transplant and will be monitored for how well their white blood cells recover. This trial is not yet recruiting, so there is still time for interested patients to learn more and discuss it with their healthcare team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must be able and willing to give written informed consent prior to any study related procedures
• • Patients with a diagnosis of multiple myeloma or lymphoma who are eligible for autologous stem cell transplant
• • All adult patients aged 18 to 75 years
• • All patients admitted to LHSC for autologous peripheral blood stem cell transplant receiving peripheral blood stem cell infusions at LHSC and post-transplant care at either LHSC or WMH.
• • Of the patients who are admitted for autologous stem cell transplant, the patients that meet the risk adapted approach for GSCF will be included in the study. The risk adapted criteria are aged 60 or greater, infusion of stem cells with a CD34 count less than or equal 3 x 10\^6/kg, prior episodes of febrile neutropenia, or at the providers clinical discretion
• • Conditioning chemotherapy as per usual clinical practice
• Exclusion Criteria:Patients satisfying the above inclusion criteria but with the following contraindications (prior to randomization) will be excluded from the study:
• • Any clinical contraindications to filgrastim, e.g. hypersensitivity to G-CSF or E. coli-derived proteins
• • Pain requiring opioids with use of filgrastim during mobilization of autologous stem cells.
• • Unable or not willing to provide written consent